Effects of high-dose methylprednisolone therapy on coagulation factors in patients with acute immune thrombocytopenic purpura

Clinical and Applied Thrombosis/Hemostasis

Volumn 11, Issue 4, 2005, Pages 489-492

  Oner, Ahmet Faik ^a,b   Bay, Ali ^a   Kuru, Mehmet ^a   Uner, Abdurrahman ^a   Arslan, Sukru ^a   Caksen, Hüseyin ^a  

^a YUZUNCU YIL UNIVERSITY   (Turkey)

^b Arastirma Hastanesi Cocuk Hastaliklari Servisi   (Turkey)

Author keywords

Autoimmune thrombocytopenic purpura; Coagulation test; Methyl prednisolone

Indexed keywords

ANTITHROMBIN III; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 11; BLOOD CLOTTING FACTOR 12; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; FIBRINOGEN; METHYLPREDNISOLONE; PROTEIN C; PROTEIN S;

ADOLESCENT; ARTICLE; AUTOIMMUNE DISEASE; BLOOD CLOTTING; BLOOD CLOTTING TEST; CHILD; CHILDHOOD DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DRUG EFFECT; DRUG MEGADOSE; FEMALE; HEMOSTASIS; HOSPITAL ADMISSION; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; MALE; MUCOSAL BLEEDING; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTHROMBIN TIME; SKIN BLEEDING;

ACUTE DISEASE; ADOLESCENT; BLOOD COAGULATION FACTORS; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; MALE; METHYLPREDNISOLONE; PURPURA, THROMBOCYTOPENIC;

EID: 27544438157     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: 10.1177/107602960501100418     Document Type: Article

References (20)

1. McClure PD. Idiopathic thrombocytopenic purpura in children: Diagnosis and management. Pediatrics 1975;55:68.
2. Mizutani H, Furubayashi T, Imai Y, et al. Mechanisms of corticosteroid action in immune thrombocytopenic purpura (ITP): Experimental studies using ITP-prone mice, (NZW x BXSB) F1. Blood 1992;79:942.
3. Oner AF, Gurgey A, Kirazli S, et al. Changes of hemostatic factors in children with acute lymphoblastic leukemia receiving combined chemotherapy including high dose methylprednisolone and L-asparaginase. Leak Lymphoma 1999;33:361.
4. Jorgensen KA, Sorensen P, Freund L. Effect of glucocorticosteroids on some coagulation tests. Acta Haematol 1982;68:39.
5. Mall V, Thomas KB, Sauter S, et al. Effect of glucocorticoids, E. coli- and Erwinia L-asparaginase on hemostatic proteins in children with acute lymphoblastic leukemia. Klin Padiatr 1999;211:205.
6. Dreyfuss F, Menczel J. The effect of corticotrophin, cortisone, and prednisone on whole blood coagulation time. J Lab Clin Med 1958;51:530.
7. Sere KM, Hackeng TM. Basic mechanisms of hemostasis. Semin Vasc Med 2003;3:3.
8. Butros LJ, Bussel JB. Intracranial hemorrhage in immune thrombocytopenic purpura: A retrospective analysis. J Pediatr Hematol Oncol 2003;25:660.
9. Teitel JM. Unexpected bleeding disorders: Algorithm for approach to therapy. Clin Lab Haematol 2000;22:26.
10. Poujol-Robert A, Rosmorduc O, Serfaty L, et al. Genetic and acquired thrombotic factors in chronic hepatitis C. Am J Gastroenterol 2004;99:527.
11. Slofstra SH, Spek CA, ten Gate H. Disseminated intravascular coagulation. Hematol J 2003;4:295.
12. Ware LB, Fang X, Matthay MA. Protein C and thrombo-modulin in human acute lung injury. Am J Physiol Lung Cell Mol Physiol 2003;285:514.
13. Matthay MA, Ware LB. Plasma protein C levels in patients with acute lung injury: Prognostic significance. Crit Care Med 2004;32:229.
14. Mori Y, Wada H, Okugawa Y, et al. Increased plasma thrombomodulin as a vascular endothelial cell marker in patients with thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Clin Appl Thromb Hemost 2001;7:5.
15. Bayazit AK, Kilinc Y. Natural coagulation inhibitors (protein C, protein S, antithrombin) in patients with sickle cell anemia in a steady state. Pediatr Int 2001;43:592.
16. Priest JR, Ramsay NK, Latchaw RE, et al. Thrombotic and hemorrhagic strokes complicating early therapy for childhood acute lymphoblastic leukemia. Cancer 1980;46:1548.
17. Nowak-Gottl U, Heinecke A, von Kries R, et al. Thrombotic events revisited in children with acute lymphoblastic leukemia: Impact of concomitant Escherichia coli asparaginase/prednisone administration. Thromb Res 2001;103:165.
18. Seifter EJ, Brooks BJ Jr, Urba WJ. Possible interactions between warfarin and antineoplastic drugs. Cancer Treat Rep 1985;69:244.
19. Tracy PB, Mann KG. Abnormal formation of the prothrombinase complex: Factor V deficiency and related disorders. Hum Pathol 1987;18:162.
20. Takaku T, Kuriyama Y, Shoji N, et al. Simultaneous development of factor V inhibitor and autoimmune thrombocytopenia in a patient with dermatomyositis. Rinsho Ketsueki 2002;43:1050.